Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Journal of Surgical Oncology

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejso.2012.07.009PMID 22809859
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study.

  2012cited by this paper
• Survival of patients with pseudomyxoma peritonei treated by serial debulking

  2010cited by this paper
• Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.

  2008cited by this paper
• Appendiceal neoplasms and pseudomyxoma peritonei: a population based study.

  2008cited by this paper
• Survival Analysis of Pseudomyxoma Peritonei Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

  2007cited by this paper
• Early Results of Surgery in 123 Patients with Pseudomyxoma Peritonei from a Perforated Appendiceal Neoplasm

  2007cited by this paper
• Pseudomyxoma Peritonei of Appendiceal Origin: A Clinicopathologic Analysis of 101 Patients Uniformly Treated at a Single Institution, With Literature Review

  2006cited by this paper
• New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?

  2006cited by this paper
• Long-term Survival Following Treatment of Pseudomyxoma Peritonei: An Analysis of Surgical Therapy

  2005cited by this paper
• International Seminars in Surgical Oncology Prognostic Indicators in Peritoneal Carcinomatosis from Gastrointestinal Cancer

  2005cited by this paper
• Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei

  2004cited by this paper
• Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.

  2004cited by this paper
• Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study

  2004cited by this paper
• Toxicity of cytoreductive surgery and hyperthermic intra‐peritoneal chemotherapy

  2004cited by this paper
• Population Pharmacokinetics and Pharmacodynamics of Mitomycin During Intraoperative Hyperthermic Intraperitoneal Chemotherapy

  2004cited by this paper
• Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality.

  2003cited by this paper
• TNM residual tumor classification revisited

  2002cited by this paper
• Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.

  2002cited by this paper
• Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy

  1999cited by this paper
• Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique

  1999cited by this paper
• Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women.

  1999cited by this paper
• Pseudomyxoma peritonei syndrome.

  1996cited by this paper
• Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.

  1996cited by this paper
• Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".

  1995cited by this paper
• Peritonectomy procedures.

  1995cited by this paper
• Pseudomyxoma Peritonei Long‐Term Patient Survival with an Aggressive Regional Approach

  1994cited by this paper
• Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon.

  1994cited by this paper
• Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study

  1994cited by this paper
• Malignant pseudomyxoma peritonei of colonic origin

  1987cited by this paper
• Pseudomyxoma Peritonei

  1986cited by this paper

• Long‐term outcomes and survival analysis of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei at a newly established peritoneal malignancy centre in Japan

  2024cites this paper
• Two-stage cytoreductive surgery for 'extensive' pseudomyxoma peritonei: A legitimate alternative or salvage strategy?

  2024cites this paper
• Peritoneales Mesotheliom und Pseudomyxoma peritonei

  2024cites this paper
• Pseudomyxoma peritonei leading to “jelly belly” abdomen: a case report and review of the literature

  2024cites this paper
• Zufallsbefund muzinöse Neoplasie der Appendix

  2023cites this paper
• Diagnostic and Therapeutic Algorithm for Appendiceal Tumors and Pseudomyxoma Peritonei: A Consensus of the Peritoneal Malignancies Oncoteam of the Italian Society of Surgical Oncology (SICO)

  2023cites this paper
• The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions

  2022cites this paper
• Enteral nutrition provides favorable postoperative outcomes for patients with pseudomyxoma peritonei: a retrospective study.

  2022cites this paper
• Cytoreductive Surgery in Peritoneal Neuroendocrine Neoplasm Metastases: The Adjuvant Endoperitoneal PRRT with 111In-Octreotide Perspective

  2021cites this paper
• Novel Perspectives in Pseudomyxoma Peritonei Treatment

  2021cites this paper
• Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer

  2021influential citation
• Improved Outcome Prediction for Appendiceal Pseudomyxoma Peritonei by Integration of Cancer Cell and Stromal Transcriptional Profiles

  2020influential citation
• Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept

  2020cites this paper
• The Prognostic Impact of Pathology on Patients With Pseudomyxoma Peritonei Undergoing Debulking Surgery: A Systematic Review and Meta-Analysis of Retrospective Studies

  2020cites this paper
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin---801 Cases from a Single Institution in China

  2020influential citation
• Surgical management for peritoneal carcinomatosis of appendiceal origin with a high-tumor burden

  2019cites this paper
• Outcome of Management of Pseudomyxoma Peritonei : National Cancer Institute

  2019influential citation
• Predictive and prognostic factors of epithelial ovarian cancer and pseudomyxoma peritonei

  2018cites this paper
• Pseudomyxoma peritonei originating from appendix tumors

  2018cites this paper
• Outcome of Management of Pseudomyxoma Peritonei: National Cancer Institute Experience

  2018cites this paper
• Long-Term Outcomes after Surgery for Appendiceal Mucinous Tumours

  2017cites this paper
• Peritoneal Dissemination of Gastrointestinal Tumors

  2016cites this paper
• The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Low-Grade Appendiceal Neoplasm: Friend or Foe?

  2016cites this paper
• Surgical treatment for high-grade pseudomyxoma peritonei originated from appendix: Analysis of clinical outcomes of repeated debulking surgery

  2016cites this paper
• Palliative Surgery for Pseudomyxoma Peritonei

  2016cites this paper
• Epidemiology: Extent of the Problem

  2015cites this paper
• The Role of Surgery

  2015cites this paper
• Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei

  2015cites this paper
• The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

  2015cites this paper
• Pseudomyxoma peritonei – a report of two cases and a review of the literature

  2015cites this paper
• Cytoreductive surgery plus perioperative intraperitoneal chemotherapy in pseudomyxoma peritonei: aspects of the learning curve.

  2014cites this paper
• Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects

  2014cites this paper
• Pseudomixoma peritoneal avanzado por adenocarcinoma mucinoso de apéndice

  2014cites this paper
• To HIPEC or Not to HIPEC? That Is The Question

  2014cites this paper
• Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin

  2014cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 886 Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer

  2013cites this paper
• Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer

  2013cites this paper
• Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis.

  2013influential citation
• Outcome of Patients with Aggressive Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy

  2013cites this paper
• Reg IV in human body and diseases

  2012cites this paper